One Two
Sie sind hier: Startseite Research Group Krohne Pharmacokinetics of VEGF-inhibitory drugs following intravitreal injection

Pharmacokinetics of VEGF-inhibitory drugs following intravitreal injection

Summary

In this project we seek to determine basic pharmacokinetic parameters such as intraocular elimination half-time of VEGF-inhibitory drugs after intravitreal injection in humans. The results will help to optimize dosing and injection intervals for these drugs.

avastin.jpg

 

References

Krohne TU, Holz FG, Meyer CH.
Pharmacokinetics of intravitreally applied VEGF inhibitors.
In: Stahl A (ed.), Anti-Angiogenic Therapy in Ophthalmology, 1st ed., pp. 139-148. Springer, Berlin, 2016. [Internet]

Krohne TU, Muether PS, Stratmann NK, Holz FG, Kirchhof B, Meyer CH, Fauser S.
Influence of ocular volume and lens status on pharmacokinetics and duration of action of intravitreal vascular endothelial growth factor inhibitors.
Retina 2015 Jan;35(1):69-74. [Pubmed]

Krohne TU, Holz FG, Meyer CH.
Pharmacokinetics of intravitreally administered VEGF inhibitors.
Ophthalmologe 2014 Feb;111(2):113-20. [Pubmed]

Krohne TU, Liu Z, Holz FG, Meyer CH.
Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans.
Am J Ophthalmol 2012 Oct;154(4):682-686. [Pubmed]

Meyer CH, Krohne TU, Holz FG.
Concentrations of unbound bevacizumab in the aqueous of untreated fellow eyes after a single intravitreal injection in humans.
Acta Ophthalmol 2012 Feb;90(1):68-70. [Pubmed]

Meyer CH, Krohne TU, Holz FG.
Intraocular pharmacokinetics after a single intravitreal injection of 1.5 mg versus 3.0 mg of bevacizumab in humans.
Retina 2011 Oct;31(9):1877-84. [Pubmed]

Krohne TU, Eter N, Holz FG, Meyer CH.
Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans.
Am J Ophthalmol 2008 Oct;146(4):508-12. [PubMed]

Eter N, Krohne TU, Holz FG.
New pharmacologic approaches to therapy for age-related macular degeneration.
BioDrugs 2006;20(3):167-79. [PubMed]

Artikelaktionen